The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response
Open accessAbstract
Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High serum levels of butyrate and propionate have been associated with resistance to anti-CTLA-4 antibodies and radiotherapy and increased Treg cell numbers in patients with melanoma.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas some studies found that gut commensals were able to impact tumor growth independently [33, 138].”
From Gut microbiota-mediated immunomodulation in tumor (2021) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationSearch and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894 · cited 3×
“FastTree 2--approximately maximum-likelihood trees for large alignments.”
MethodUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 1×
“(77) were computed between each pair of samples using QIIME.”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“SCFAs produced by colonic Clostridia were also shown to induce the differentiation of colonic Treg cells in mice (68).”
BackgroundRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“Although DCs can also modulate T cells in a butyrate-dependent manner (67), to our knowledge, the direct impact on antigen presentation in the context of RT has not been investigated.”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760 · cited 1×
“org ily Clostridia (gram-positive bacteria), generating SCFAs such as C4, C3, and C2 (62).”
BackgroundInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554 · cited 2×
“Because T regulatory cells (Tregs) have been reported to be influenced by microbiota composition (15, 34) and because Tregs influence RT antitumor effects (35, 36), we evaluated the impact of the vancomycin treatment on Tregs in the tumor.”
BackgroundInteractions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“(14) demonstrated that depletion of certain gram-positive bacteria, including SFB, influenced the local and systemic Th17 development, suggesting that there are different mechanisms involved in the 2 models.”
BackgroundInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927 · cited 1×
“Several cytokines contribute to the priming of the effector functions of cytotoxic T cells, and IFN-γ is known to play a critical role in both differentiation and effector functions of CD8+ cytolytic T cells in the antitumor immune response (38, 39).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“These findings and our data suggest that different bacterial species may be redundant in their impact on the immune system by the presence of possibly overlapping metabolites, with different possible outcomes for tumor growth (60).”
BackgroundInduction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752 · cited 1×
“Moreover, a direct correlation exists between the presence of specific bacteria in the gut microbiota and T cell development and differentiation (15, 16).”
BackgroundPyNAST: a flexible tool for aligning sequences to a template alignment
Caporaso, J. G., Bittinger, K., Bushman, F. D., DeSantis, T. Z., Andersen, G. L., & Knight, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp636 · Cited by 3,396 · cited 3×
“Representative sequences were aligned with PyNAST (75) and used”
MethodSelf-citationShort chain fatty acids in human large intestine, portal, hepatic and venous blood
Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., & Macfarlane, G. T. (1987) · Gut · doi:10.1136/gut.28.10.1221 · Cited by 3,119 · cited 1×
“Since the SCFA concentrations in the blood and tissues have been reported to be substantially lower than in intestinal content (47), we examined the effects of vancomycin in both the TDLNs and the tumors by collecting tissue from tumor-bearing animals that were either untreated (control) or treated with vancomycin.”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Because T regulatory cells (Tregs) have been reported to be influenced by microbiota composition (15, 34) and because Tregs influence RT antitumor effects (35, 36), we evaluated the impact of the vancomycin treatment on Tregs in the tumor.”
BackgroundGut Microbiota Metabolism of Dietary Fiber Influences Allergic Airway Disease and Hematopoiesis
Trompette, A., Gollwitzer, E. S., Yadava, K., Sichelstiel, A. K., Sprenger, N., Ngom-Bru, C., Blanchard, C., Junt, T., Nicod, L. P., Harris, N. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3444 · Cited by 2,862
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Since T cells mediate both local and systemic antitumor immune response after RT (32, 33), we initially tested the overall presence of infiltrating CD3+ T cells within tumor sections from both irradiated and abscopal B16-OVA tumors by immunohistochemistry.”
BackgroundIntestinal Short Chain Fatty Acids and their Link with Diet and Human Health
Ríos-Covián, D., Ruas-Madiedo, P., Margolles, A., Gueimonde, M., de los Reyes-Gavilán, C. G., & Salazar, N. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00185 · Cited by 2,179 · cited 1×
“SCFAs are saturated aliphatic organic acids that contain between 1 –6 carbon atoms of which acetate (2 carbon atoms [C2]), propionate (3 carbon atoms [C3]), and butyrate (4 carbon atoms [C4]) represent 95% of total SCFAs present in the intestine (44, 45).”
BackgroundThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · cited 3×
“also showed that the antitumor immune response to cyclophosphamide therapy was mediated by the specific phenotype of Th17 cells (20).”
BackgroundMethodDNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834 · cited 2×
“Previously published work has shown that in breast and colorectal cancers, cross-priming can be affected in a dose-dependent manner due to the activation of TREX1 nucleases at doses above 8 Gy (13).”
BackgroundSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Samuel, B. S., Shaito, A., Motoike, T., Rey, F. E., Backhed, F., Manchester, J. K., Hammer, R. E., Williams, S. C., Crowley, J., Yanagisawa, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808567105 · Cited by 1,564
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324 · cited 2×
“Recent studies have shown that appropriate dosing and scheduling of high-dose RT can lead to increased T cell priming and T cell–dependent tumor regression (28).”
BackgroundMethodFunctional significance of the perforin/granzyme cell death pathway
Trapani, J. A., & Smyth, M. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri911 · Cited by 1,291 · cited 1×
“Several cytokines contribute to the priming of the effector functions of cytotoxic T cells, and IFN-γ is known to play a critical role in both differentiation and effector functions of CD8+ cytolytic T cells in the antitumor immune response (38, 39).”
BackgroundPluznick, J. L., Protzko, R. J., Gevorgyan, H., Peterlin, Z., Sipos, A., Han, J., Brunet, I., Wan, L.-X., Rey, F., Wang, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215927110 · Cited by 1,191
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Lin, K. Y., Guarnieri, F., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. ‐. (1996) · PubMed · Cited by 1,003
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878 · cited 2×
“Hypofractionated RT activates the cross-priming capacity of tumor-infiltrating DCs, with IFN-β serving as the master regulator of tumor antigen cross-presentation (42).”
BackgroundAAPM protocol for 40–300 kV x‐ray beam dosimetry in radiotherapy and radiobiology
Ma, C. ‐., Coffey, C. W., DeWerd, L. A., Liu, C., Nath, R., Seltzer, S. M., & Seuntjens, J. P. (2001) · Medical Physics · doi:10.1118/1.1374247 · Cited by 816
Park, C., Papiez, L., Zhang, S., Story, M., & Timmerman, R. D. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.059 · Cited by 651 · cited 1×
“High-dose, hypofractionated radiotherapy was initially introduced for intracranial tumors as stereotactic radiosurgery and was later extended to extracranial sites as stereotactic body RT (SBRT) (8–30 Gy/fraction) (2).”
BackgroundRadiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
Reynders, K., Illidge, T., Siva, S., Chang, J. Y., & De Ruysscher, D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.011 · Cited by 574
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Multiple roles for CD4+ T cells in anti‐tumor immune responses
Kennedy, R., & Celis, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00616.x · Cited by 511 · cited 1×
“IFN-γ is produced by T cells and is a signature of the Th1 phenotype (41).”
BackgroundImage-guided radiotherapy: from current concept to future perspectives
Jaffray, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.194 · Cited by 496 · cited 1×
“org Introduction Radiotherapy (RT) is a well-established antitumor treatment, with more than 50% of newly diagnosed cancer patients with solid tumors receiving RT at some point during their treatment, usually in combination with chemotherapy (1).”
BackgroundMicrobiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
B16 as a Mouse Model for Human Melanoma
Overwijk, W. W., & Restifo, N. P. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s39 · Cited by 434 · cited 1×
“Although an increase in the total number of T cells infiltrating the tumor in the vancomycin-alone group was observed, the OVA T cell–specific response was, unexpectedly, not improved in the same group, suggesting that in nontreated tumors, cross presentation may increase the recognition of other TAAs (49, 50).”
BackgroundHill, D. A., Hoffmann, C., Abt, M. C., Du, Y., Kobuley, D., Kirn, T. J., Bushman, F. D., & Artis, D. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.132 · Cited by 431 · cited 1×
“Vancomycin (mostly targeting gram-positive bacteria) or a neomycin/metronidazole (Neo/Met) regimen (mostly targeting gram-negative bacteria) was administered orally in C57/Bl6 mice (27).”
MethodSelf-citationThe effect of short-chain fatty acids on human monocyte-derived dendritic cells
Nastasi, C., Candela, M., Bonefeld, C. M., Geisler, C., Hansen, M., Krejsgaard, T., Biagi, E., Andersen, M. H., Brigidi, P., Ødum, N., et al. (2015) · Scientific Reports · doi:10.1038/srep16148 · Cited by 414 · cited 3×
“Butyrate and propionate treatment of human DCs significantly reduced LPS-induced Il6 mRNA and Il12 gene expression and enhanced leukocyte trafficking, and SCFAs strongly reduced the release of several proinflammatory chemokines (46).”
BackgroundMethodInfluentialIn vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties.
Poste, G. H., Doll, J., Hart, I. R., & Fidler, I. J. (1980) · PubMed · Cited by 408
Antimicrobial resistance in gram-positive bacteria
Rice, L. B. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.220 · Cited by 381
Radiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 363
Short- and long-term effects of oral vancomycin on the human intestinal microbiota
Isaac, S., Scher, J. U., Djukovic, A., Jiménez, N., Littman, D. R., Abramson, S. B., Pamer, E. G., & Ubeda, C. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw383 · Cited by 318 · cited 1×
“We selected vancomycin, a glycopeptide antibiotic that acts mainly on gram-positive bacteria, as an agent to specifically perturb the gut microbiota, because vancomycin is very poorly absorbed after oral administration and does not enter the systemic circulation (22, 23).”
BackgroundGPR41 and GPR43 in Obesity and Inflammation – Protective or Causative?
Ang, Z., & Ding, J. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00028 · Cited by 304
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297 · cited 1×
“Tumor cells succumbing to ICD stimulate antigen presenting cells (APCs), such as dendritic cells (DCs), to efficiently engulf tumor antigens and cross-present them to CD8+ cytotoxic T lymphocytes (6, 7).”
BackgroundAntimicrobial Resistance in Gram-Positive Bacteria
Rice, L. B. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.012 · Cited by 276
Oweida, A., Hararah, M. K., Phan, A., Binder, D., Bhatia, S., Lennon, S., Bukkapatnam, S., Van Court, B., Uyanga, N., Darragh, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 274 · cited 1×
“Because T regulatory cells (Tregs) have been reported to be influenced by microbiota composition (15, 34) and because Tregs influence RT antitumor effects (35, 36), we evaluated the impact of the vancomycin treatment on Tregs in the tumor.”
BackgroundMuroyama, Y., Nirschl, T. R., Kochel, C. M., Lopez-Bujanda, Z., Theodros, D., Mao, W., Carrera-Haro, M. A., Ghasemzadeh, A., Marciscano, A. E., Velarde, E., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0040 · Cited by 215 · cited 1×
“Because T regulatory cells (Tregs) have been reported to be influenced by microbiota composition (15, 34) and because Tregs influence RT antitumor effects (35, 36), we evaluated the impact of the vancomycin treatment on Tregs in the tumor.”
BackgroundEffects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.
Mehrotra, P. T., Wu, D., Crim, J. A., Mostowski, H. S., & Siegel, J. P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2444 · Cited by 203 · cited 1×
“Previously, we reported that vancomycin in combination with T cell therapy induces the expansion of CD8+ DCs and affects the level of IL-12; in turn, IL-12 stimulates the production of IFN-γ and promotes both Th1 differentiation and CTL activity (21, 40).”
BackgroundPharmacokinetics of vancomycin
Moellering, R. C. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.43 · Cited by 178 · cited 1×
“We selected vancomycin, a glycopeptide antibiotic that acts mainly on gram-positive bacteria, as an agent to specifically perturb the gut microbiota, because vancomycin is very poorly absorbed after oral administration and does not enter the systemic circulation (22, 23).”
BackgroundGut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175 · cited 5×
“Recently, our group demonstrated in preclinical models that gut microbiota influence the impact of ACT, which is in line with the present results that vancomycin treatment increases the antitumor effects of ACT (21).”
BackgroundResultInfluentialSelf-citationNovel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173 · cited 1×
“Combination of RT with immunotherapy has recently garnered considerable clinical interest due to its potential for transforming RT from a modality used to treat localized disease to a modality used to treat systemic malignancies (9).”
BackgroundTurning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette, M., Marabelle, A., & Houot, R. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.010 · Cited by 161 · cited 1×
“Although an increase in the total number of T cells infiltrating the tumor in the vancomycin-alone group was observed, the OVA T cell–specific response was, unexpectedly, not improved in the same group, suggesting that in nontreated tumors, cross presentation may increase the recognition of other TAAs (49, 50).”
BackgroundDerer, A., Deloch, L., Rubner, Y., Fietkau, R., Frey, B., & Gaipl, U. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00505 · Cited by 119 · cited 1×
“Tumor cells succumbing to ICD stimulate antigen presenting cells (APCs), such as dendritic cells (DCs), to efficiently engulf tumor antigens and cross-present them to CD8+ cytotoxic T lymphocytes (6, 7).”
BackgroundMaity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T. D., Gruber, A. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3065 · Cited by 108 · cited 2×
“catalog BE0117) or rat IgG2b isotype control (InVivoMAb LTF-2, BioXCell, catalog BE0090) by intraperitoneal injection (37).”
BackgroundBidirectional interactions between indomethacin and the murine intestinal microbiota
Liang, X., Bittinger, K. L., Li, X., Abernethy, D. R., Bushman, F. D., & FitzGerald, G. A. (2015) · eLife · doi:10.7554/elife.08973 · Cited by 108 · cited 1×
“The bacterial population in the cecum has been reported to be more abundant in Firmicutes, the phylum of SCFA-producing gut bacteria, relative to feces (48).”
BackgroundSelf-citationLu, Y., Yao, D., & Chen, C. (2013) · Metabolites · doi:10.3390/metabo3040993 · Cited by 101
Fermentation of non-digestible oligosaccharides by human colonic bacteria
Gibson, G. R., Willems, A., Reading, S., & COLLINS, M. D. (1996) · Proceedings of The Nutrition Society · doi:10.1079/pns19960087 · Cited by 89 · cited 1×
“The gut microbiota aids host digestion and generates a large repertoire of metabolites, including short-chain fatty acids (SCFAs) that constitute the major products of bacterial fermentation (43).”
BackgroundUnlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy
Wattenberg, M. M., Fahim, A., Ahmed, M. M., & Hodge, J. W. (2014) · Radiation Research · doi:10.1667/rr13374.1 · Cited by 73
Facciabene, A., Sanctis, F. D., Pierini, S., Reis, E. S., Balint, K., Facciponte, J. G., Rueter, J., Kagabu, M., Magotti, P., Lanitis, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326442 · Cited by 73 · cited 1×
“Tumor cells (1 × 105) were incubated for 24 hours with 1 × 105 T cells from OT1 mice or from E6/7 immunized mice in IFN-γ ELISPOT plates (71).”
MethodSelf-citationMetastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence.
Netland, P. A., & Zetter, B. R. (1985) · The Journal of Cell Biology · doi:10.1083/jcb.101.3.720 · Cited by 50 · cited 1×
“The following day, the mice were challenged subcutaneousUsing both a melanoma model (24, 25) and a HPV E6/7-expressing lung and cervical cancer model (26), we found that the antitumor effects elicited by RT in tumor-bearing mice are positively impacted by treatment with vancomycin.”
MethodA Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma
Pierini, S., Fang, C., Rafail, S., Facciponte, J. G., Huang, J., Sanctis, F. D., Morgan, M. A., Uribe‐Herranz, M., Tanyi, J. L., & Facciabene, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500281 · Cited by 34 · cited 1×
“On day 7, cells were collected and adjusted to 1 × 106 cells/mL and incubated with 1 μg/ml LPS (Invivogen, catalog tlrl-eblps) overnight (69).”
MethodSelf-citationBowers, J. S., Nelson, M. H., Kundimi, S., Bailey, S. R., Huff, L. W., Schwartz, K. M., Cole, D. J., Rubinstein, M. P., & Paulos, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2294 · Cited by 32 · cited 1×
“As demonstrated by previous work in chemotherapy and systemic-based RT, therapies such as total body irradiation (TBI) have a direct effect on gut microbiota and damage to the gut epithelial barrier, with possible transient intraperitoneal extraversion and inflammation, which can in turn influence tumor response (20,…”
MethodHypofractionated Radiotherapy in Non Small Cell Lung Cancer: A Review of the Current Literature
Beli, I., Koukourakis, G. V., Platoni, K., Tolia, M., Kelekis, N., Kouvaris, J., Syrigos, C., Mystakidou, K., Varveris, C., & Kouloulias, V. (2010) · Reviews on Recent Clinical Trials · doi:10.2174/157488710791233608 · Cited by 26
Microbiote intestinal et réponses aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2016) · médecine/sciences · doi:10.1051/medsci/20163211013 · Cited by 24
Abstract 4961: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Pierini, S., Guedan, S., Bushman, F., June, C., & Facciabene, A. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4961
Self-citation
Research works printed but not linked: 1
- 10.1038/nature14292 · DOI · Paper page
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
“In a study of melanoma and lung cancer models, vancomycin can enhance the anti-tumor response induced by radiotherapy in mice by increasing CD8+ T cell infiltration and IFN-γ expression.(358) Many studies have shown that antibiotics can prevent cancer development or attenuate tumor proliferation.”
BackgroundThe microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“Radiotherapy of tumor lesions was more effective when vancomycin eliminated Clostridiales-derived immunosuppressivemetabolites (butyrate and propionate) putatively by increasing DC antigen presentation and concomitant CD8 T cell priming (72); conversely, gut microbial–derived propionate and tryptophan pathway metaboli…”
BackgroundCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
“Beyond those associations, mouse studies demonstrated that oral vancomycin-induced depletion of Gram-positive gut commensals was correlated with enhanced radiotherapy effectiveness in melanoma, lung, and cervical cancer models, potentially mediated through IFNg and CD8 T cell– dependent mechanisms (Uribe-Herranz et al…”
BackgroundBehary, J., Amorim, N., Jiang, X.-T., Raposo, A., Gong, L., McGovern, E., Ibrahim, R., Chu, F., Stephens, C., Jebeili, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20422-7 · Cited by 470
The role of gut microbiota in cancer treatment: friend or foe?
Cheng, W. Y., Wu, C.-Y., & Yu, J. (2020) · Gut · doi:10.1136/gutjnl-2020-321153 · Cited by 384
Metadata
- Authors
- Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., Mesaros, C. A., Snyder, N. W., Bushman, F., Koumenis, C., & Facciabene, A.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Drexel University (US)
- Corresponding author
- Koumenis, Constantinos
- Facciabene, Andrea
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2019-12-09
- Volume
- 130
- Issue
- 1
- Pages
- 466-479
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6934221
- OpenAlex
- W2993330612
- Cited by
- 316
- References
- 79
- Citations by year
- 2026: 37 · 2025: 59 · 2024: 60 · 2023: 52 · 2022: 44 · 2021: 43 · 2020: 21
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Children's Hospital of Philadelphia
- University of Pennsylvania
- National Institutes of Health
- National Cancer Institute (R01CA116779, R01CA219871)
- National Institute of General Medical Sciences (R01GM132261)
- National Institute of Environmental Health Sciences (P30ES013508)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, radiotherapy, dendritic cells, antigen presentation, antitumor immunity, vancomycin, butyrate, CD8+ T cells, interferon-gamma, abscopal effect
- MeSH terms
- Gastrointestinal Microbiome, Animals, Antigens, Neoplasm, Butyrates, Dendritic Cells, Female, Neoplasms, Experimental, Antigen Presentation, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.